SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "L773:1651 226X srt2:(1995-1999)"

Search: L773:1651 226X > (1995-1999)

  • Result 11-20 of 125
Sort/group result
   
EnumerationReferenceCoverFind
11.
  •  
12.
  •  
13.
  • Brahme, A (author)
  • Biologically based treatment planning
  • 1999
  • In: Acta oncologica (Stockholm, Sweden). - : Informa UK Limited. - 0284-186X .- 1651-226X. ; 3838 Suppl 13, s. 61-68
  • Journal article (peer-reviewed)
  •  
14.
  •  
15.
  • Brun, Eva, et al. (author)
  • Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET
  • 1997
  • In: Acta Oncologica. - : Informa UK Limited. - 1651-226X .- 0284-186X. ; 36:7, s. 741-747
  • Journal article (peer-reviewed)abstract
    • The development of alternative treatment regimens in clinical oncology has increased the need for early prediction of cancer therapy outcome. The aim of this study was, early in the treatment phase, to identify patients with advanced head and neck cancer, responding or not responding to initiated therapy. The tumour metabolic rate of glucose (MRgl) examined by 2-18FDG-PET was determined in 17 patients before and after the first weeks of either radiotherapy (16-35 Gy) or one course of combination chemotherapy. Metabolic values uptake values normalized to plasma activity integrals--were correlated to loco-regional outcome, as evaluated 5-6 weeks after completion of treatment. Initial low tumour MRgl (<20 micromol/min/100 g tissue), in primary lesions or regional metastases, predicted a local complete response. When a high initial tumour MRgl was found, the magnitude of the reduction of MRgl in the second PET examination might be an adjunct in predicting local tumour response.
  •  
16.
  • Carlsson, Jörgen, et al. (author)
  • Conjugate chemistry and cellular processing of EGF-dextran
  • 1999
  • In: Acta Oncologica. - 0284-186X .- 1651-226X. ; 38:3, s. 313-321
  • Journal article (peer-reviewed)abstract
    • Conjugates with specific binding to the epidermal growth factor receptor, EGFR, of interest for radionuclide based imaging and therapy were prepared using mouse epidermal growth factor, mEGF, and dextran. In one type of conjugate, mEGF was coupled to dextran by reductive amination in which the free amino group on the mEGF N-terminal reacted with the aldehyde group on the reductive end of dextran. The end-end coupled conjugate could be further activated by the cyanopyridinium agent CDAP, thereby introducing tyrosines to the dextran part. In the other type of conjugate, the cyanylating procedure using CDAP was applied, first to activate dextran and then allowing for the amino terminus of mEGF to randomly attach to the dextran. In the latter case, radionuclide-labelled tyrosines or glycines could be added in the same conjugation step. All types of mEGF-dextran conjugates had EGFR-specific binding since the binding could be displaced by an excess of non-radioactive mEGF. The conjugates were to a large extent internalized in the test cells and the associated radioactivity was retained intracellularly for different times depending on both the type of cells and conjugate applied. Different intracellular 'traffic routes' for the radionuclides are discussed as well as applications for both imaging and therapy.
  •  
17.
  •  
18.
  •  
19.
  •  
20.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 11-20 of 125

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view